Originally published as JCO Early Release 10.1200/JCO.2009.22.3305 on April 27 2009

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Abali, H. Articles by Mertsoylu, H. PubMed PubMed Citation Articles by Abali, H. Articles by Mertsoylu, H. Related Articles Related Articles Related Reply Social Bookmarking                            What's this?

Immediate or Delayed Docetaxel: Does Progression-Free Survival Really Reflect Two Strategies?

Baçskent Üniversitesi Tp Fakültesi ç Hastalklar Tbbi Onkoloji BD, Ankara, Turkey

To the Editor:

We have read the article by Fidias et al¹ with great interest. It made a valuable contribution from a clinical point of view. Their trial was designed to answer one question that clinicians come across frequently in everyday oncological management of patients with advanced non–small-cell lung cancer: should nonprogressing patients after a sufficient amount of first-line therapy proceed with immediate second-line chemotherapy, or should they defer it until documentation of first progression? The authors stated that progression-free survival (PFS) in the immediate docetaxel arm was significantly longer than that in the delayed docetaxel arm (5.7 v 2.7 months; P = .0001) and that there was a trend of improved overall survival (OS) in the same arm (12.3 v 9.7 months; P = .0853), probably owing to the greater number of patients who were able to receive treatment in the immediate docetaxel arm. OS was the primary end point. We have some comments on PFS, one of the secondary end points.

Rather than one PFS, the delayed arm has actually two PFS rates by definition, given that patients should wait until the documentation of progression before receiving chemotherapy: one from random assignment to documentation of first progression just before time of docetaxel institution (PFS₁), and one from docetaxel institution to the documentation of progression while still receiving chemotherapy (PFS₂). However, there is only one sort of PFS in the immediate docetaxel arm: the one from random assignment to progression on docetaxel chemotherapy. Although it is not clear from the article, the investigators probably reported a comparison of PFS₁ in the delayed arm with PFS in the immediate arm. We think that this may be the reason why there was a strong statistical difference (2.7 v 5.7 months; P = .0001). Such a comparison does not fully reflect the expected answer to the question of delayed versus immediate docetaxel after first-line therapy. Rather, it gives information concerning the question if docetaxel improves PFS after four cycles of gemcitabin-carboplatin in nonprogressing patients. It is highly probable that no PFS difference between delayed and immediate docetaxel would have been detected if the investigators had calculated PFS from the time of random assignment to progression during docetaxel chemotherapy for both arms.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

REFERENCE

1. Fidias PM, Dakhil SR, Lyss AP, et al: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non–small-cell lung cancer. J Clin Oncol 27:591–598, 2009.[Abstract/Free Full Text]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Articles

• Immediate or Delayed Docetaxel: Does Progression-Free Survival Really Reflect Two Strategies?
  Hüseyin Abali, Umut Disel, Fatih Köse, Ahmet Sezer, and Hüseyin Mertsoylu
  JCO 2009 27: 2889 [Full Text]
• Reply to H. Abali et al
  Panos Fidias
  JCO 2009 27: 2889 [Full Text]
• Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
  Panos M. Fidias, Shaker R. Dakhil, Alan P. Lyss, David M. Loesch, David M. Waterhouse, Jane L. Bromund, Ruqin Chen, Maria Hristova-Kazmierski, Joseph Treat, Coleman K. Obasaju, Martin Marciniak, John Gill, and Joan H. Schiller
  JCO 2009 27: 591-598 [Abstract] [Full Text]

Related Reply

• Reply to H. Abali et al
  Panos Fidias
  JCO 2009 27: 2889 [Full Text]

This article has been cited by other articles:

				P. Fidias Reply to H. Abali et al J. Clin. Oncol., June 10, 2009; 27(17): 2889 - 2889. [Full Text] [PDF]

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Abali, H. Articles by Mertsoylu, H. PubMed PubMed Citation Articles by Abali, H. Articles by Mertsoylu, H. Related Articles Related Articles Related Reply Social Bookmarking                            What's this?